Danske Bank’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
Other funds holding BCRX
JHC
Danske Bank's BCRX Position: Q3 2026 in Review
Danske Bank held its BioCryst Pharmaceuticals (BCRX) position steady in Q3 2026 at 2 shares worth $17. The position accounts for ﹤0.01% of the portfolio, ranked #1049.
Danske Bank first reported a position in BCRX in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.45M in Q1 2025. 331 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.
- Danske Bank held 2 shares of BioCryst Pharmaceuticals worth $17 as of Q3 2026.
- Danske Bank left its BioCryst Pharmaceuticals share count unchanged in Q3 2026.
- BioCryst Pharmaceuticals made up ﹤0.01% of Danske Bank's portfolio in Q3 2026, its #1049 holding.
- Danske Bank first reported a position in BioCryst Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
- Danske Bank's BioCryst Pharmaceuticals position peaked at $1.45M in Q1 2025.
- 331 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.
Based on Danske Bank's 13F filing for Q3 2026, filed 9 Nov 2026.